Sean S. Mahase, MD

@MayoFL_RORes Congratulations @FSamaan ! Excited to see what you accomplish at @MayoFL_RORes

We’re thrilled to announce our Match and officially welcome Fadi Samaan to our Radiation Oncology residency! 🎉✨ We’re so excited to have such an outstanding candidate join our team and can’t wait to see all the great things ahead! 🌟💙 #RadOnc

Huge congratulations to Fadi Samaan on matching into Radiation Oncology at Mayo Clinic Florida! 🎉 Your hard work and passion have truly paid off. Wishing you all the best as you begin this exciting next chapter!

Excited to share our latest publication on #BNCT for high-grade CNS tumors A promising high-LET, biologically targeted approach for radioresistant disease - and we’re moving toward becoming the first BNCT center in the U.S! #radonc #BrainCancer mdpi.com/3796404

Our new @uscbtc study published in the Journal of Neuro-Oncology @JNeurooncol In a national dataset of >3.3M patients, we found: • BSO alone → lower lifetime risk of meningioma • HRT → increased risk • BSO + HRT → highest risk, particularly in women with hormone-driven conditions (fibroids, endometriosis, gynecologic malignancy) Interestingly, patients who developed meningiomas after BSO + HRT were less likely to undergo surgical resection, suggesting these tumors may be more indolent. Important implications for hormonal exposure, risk stratification, and counseling after surgical menopause. Great work by Will Zeng + our USC team. Study:doi.org/10.1007/s11060… #Neurosurgery #endocrinology #obgyn @NeurosurgeryUSC

Officially in print! Our ASTRO Clinical Practice Guideline for #GastricCancer #PracticalRO @AnkerUVMRadOnc @ASTRO_org @SalmaJabbour1 practicalradonc.org/article/S1879-…

Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image). Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.10…

Can Quadshot ☢️be used as bridging therapy for lymphoma? In this case series, 11 patients w/ lymphoma received Quadshot ☢️ (14-14.8 Gy in 4 BID over 2 days) 🔘At median 5.5mo post ☢️, 9/10 had complete metabolic response (Deauville 1-2) 🔘1 patient required a 2nd Quadshot cycle due to recurrent sx 🔘For pts w/ planned next-line systemic therapy (n=10), tx was initiated without delay due to ☢️ 🔗 - tinyurl.com/5n73rct3 @ASTRO_org @HarvardRadOnc #radonc #lymphoma

Read it in the #RedJournal: Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group-Led Report from the National Clinical Trials Network. @NRGOnc tinyurl.com/rjkovalchuk

@SprakerMDPhD Link! nejm.org/doi/full/10.10… Great, balanced piece by our chair @BobTimmermanMD.

Interesting case of anisocoria induced by cold post protons for chordoma, check it out. @ASTRO_org @naptprotons practicalradonc.org/article/S1879-…

The Thing Cardiologists Don't Know Yet There is a treatment for refractory ventricular tachycardia that takes 15 minutes, requires no incision, no catheter, no general anesthesia, and has a 1-year survival rate of 73%. Most cardiologists have never referred a patient for it. Most electrophysiologists don't know which radiation oncologist in their city offers it. It's called STAR: Stereotactic Arrhythmia Radiotherapy. It maps the arrhythmogenic scar in the heart using the same EP mapping that guides catheter ablation, then delivers a single focused radiation dose with millimeter precision. The RADIATE-VT trial is randomizing patients right now. The specialty that built its entire identity around tumor control just quietly became a cardiology treatment option. Kudos to our colleagues who keep pushing the boundaries of our specialty for the benefit of patients.

Trying to determine if a patient has recurrent disease vs. adverse radiation effect after radiation therapy for brain mets? 18F-fluciclovine PET criteria based on full histopath in this prospective phase 2 study! authors.elsevier.com/sd/article/S03…

🚨🚨Multiple Brain Mets Randomized Trial🚨 · Significantly less symptom burden with SRS compared to HA-WBRT · Better ADL, cognition & KPS after SRS · SRS Standard of Care 5-20 brain mets jamanetwork.com/journals/jama/…

📢 New Publication | Neurosurgery Proud to share our latest work from the @USCBTC, led by Ishan Shah, now published in @NeurosurgeryCNS 🔍 Key finding: A simple, quantitative T2 MRI signal intensity ratio (TCTI) reliably predicts intraoperative meningioma consistency — with strong diagnostic performance (AUC up to 0.87). Preop imaging can help surgeons anticipate tumor firmness, optimize surgical planning + approaches, instrumentation & enhance patient counseling. A practical tool for surgical planning. #Neurosurgery #Meningioma #BrainTumor #SkullBase #NeuroOncology #MRI @NeurosurgeryUSC Link: doi.org/10.1227/neu.00…

ACRO recently collaborated on a consensus statement on standards for dose evaluation and reporting in patients with multiple courses of #radiationtherapy. The policy review is now published in @TheLancetOncol. Check it out: sciencedirect.com/science/articl…

So thrilled to have led this 🌍🌏🌎 international Delphi project with the pioneers of #simfreeRT. 📣 Consensus guidelines for clinical implementation of non-adaptive sim-free RT now available in AdvRadOnc! ➡️ doi.org/10.1016/j.adro…

In the Journal of Neuro-Oncology, a new study by Dr. Shepard, my team at UVA, and other IRRF colleagues on pineal gland metastases

Happy to share our experience using MRI-guided PULSAR re-irradiation for high-risk recurrent WHO grade 4 gliomas 🧠 Proud of this work and this incredible team! doi.org/10.1016/j.ijro…

Happy to share our last article on SRS for resected BM. Our resuls indicate that both 3 × 9 Gy and 5 × 6 Gy are effective SRS treatment modalities associated with high local control and low risk of symptomatic radionecrosis. link.springer.com/10.1007/s11060… @SapienzaRoma